Cancer drug combo trial halted early: what it means for patients
NCT ID NCT03506373
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, ibrutinib and ixazomib, in 21 people with Waldenström macroglobulinemia, a rare blood cancer. The goal was to see if the combo could shrink or control the cancer. The trial was stopped early, so results are limited, but the approach aimed to block enzymes that help cancer grow.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT WALDENSTROM MACROGLOBULINEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224-9980, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive drug outperform standard therapy in waldenstrom macroglobulinemia?
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Smartwatches track hidden heart risk in blood cancer patients
- Can a tailored exercise and diet plan beat cancer fatigue?
- Immunotherapy combo shows promise for Tough-to-Treat blood cancers
- New drug duo shows promise for rare blood cancer